TY - JOUR
T1 - Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas
AU - Edmonson, John H.
AU - Buckner, Jan C.
AU - Long, Harry J.
AU - Loprinzi, Charles L.
AU - Schaid, Daniel J.
N1 - Funding Information:
Received January 5, 1989; revised March 16, 1989; accepted March 20, 1989. Supported in part by Public Healdi Service grants CM-57733 (Division of Cancer Treatment) and CA-15083 from the National Cancer Institute, National. Institutes of Health, Department of Health and Human Services. Division of Medical Oncology, Mayo Clinic, Rochester, MN. * Correspondence to: Dr. John H. Edmonson, Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905.
PY - 1989/6/7
Y1 - 1989/6/7
N2 - Between April 1987 and July 1988, 44 adults with histologically proven, objectively assessable advanced nonosseous sarcomas were treated with 2.5 g of ifosfamide/m2,100 mg of etoposide/m2, and 2.5 g of mesna/m2 (500 mg/m2 × 5) daily for 3 consecutive days every 4 weeks. This regimen was generally well tolerated as outpatient treatment. Because of the potential CNS effects of ifosfamide, we recommend that elderly patients, persons receiving high doses of opiates, and patients susceptible to the syndrome of vertigo, perspiration, and hypotension (without tachycardia) be hospitalized for treatment At initial treatment, leukocyte count nadirs were <1,000/μL and platelet count nadirs were /100,000/μL in 38% and 15%, respectively, of the 39 patients for whom such data were available. Objective tumor regression occurred in ≈16% (95% confidence interval, 7%-30%) of the 44 patients (six, partial responses; one, complete response). For the 44 patients, median time to disease progression was 2.3 months; median time to death was 9.4 months. While this regimen was effective in three of 20 patients who had been previously treated with a doxorubicin-based regimen, only one of the 12 patients whose tumors had been primarily refractory to the doxorubicin-based regimen experienced objective tumor regression on our ifosfamide-based regimen. [J Natl Cancer Inst 81:863-866, 1989]
AB - Between April 1987 and July 1988, 44 adults with histologically proven, objectively assessable advanced nonosseous sarcomas were treated with 2.5 g of ifosfamide/m2,100 mg of etoposide/m2, and 2.5 g of mesna/m2 (500 mg/m2 × 5) daily for 3 consecutive days every 4 weeks. This regimen was generally well tolerated as outpatient treatment. Because of the potential CNS effects of ifosfamide, we recommend that elderly patients, persons receiving high doses of opiates, and patients susceptible to the syndrome of vertigo, perspiration, and hypotension (without tachycardia) be hospitalized for treatment At initial treatment, leukocyte count nadirs were <1,000/μL and platelet count nadirs were /100,000/μL in 38% and 15%, respectively, of the 39 patients for whom such data were available. Objective tumor regression occurred in ≈16% (95% confidence interval, 7%-30%) of the 44 patients (six, partial responses; one, complete response). For the 44 patients, median time to disease progression was 2.3 months; median time to death was 9.4 months. While this regimen was effective in three of 20 patients who had been previously treated with a doxorubicin-based regimen, only one of the 12 patients whose tumors had been primarily refractory to the doxorubicin-based regimen experienced objective tumor regression on our ifosfamide-based regimen. [J Natl Cancer Inst 81:863-866, 1989]
UR - http://www.scopus.com/inward/record.url?scp=0024333892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024333892&partnerID=8YFLogxK
U2 - 10.1093/jnci/81.11.863
DO - 10.1093/jnci/81.11.863
M3 - Article
C2 - 2498525
AN - SCOPUS:0024333892
SN - 0027-8874
VL - 81
SP - 863
EP - 866
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 11
ER -